Contact Us




Sorafenib, a systemic therapy for hepatocellular carcinoma

Nahum Méndez-Sánchez, Francisco Vásquez-Fernández, Daniel Zamora-Valdés, Uribe Misael


Hepatocellular carcinoma is a lethal disease that requires a multidisciplinary approach and management. Surgical therapy offers long-term survival; however, few patients are candidates. There has been no accepted systemic therapy for this disease until recently. This article briefly discusses the role of RAS/RAF/MEK/ ERK signaling pathway in the pathogenesis of the disease and the promising role of sorafenib for advanced disease.

Key words. Liver cancer, hepatocellular carcinoma, HCV, HBV, sorafenib

Article Metrics

The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for the Study of the Liver and the Canadian Association for the Study of the Liver

© 2018 Annals of Hepatology. All rights reserved Privacy Policy